Compare BLX & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLX | ANAB |
|---|---|---|
| Founded | 1977 | 2005 |
| Country | Panama | United States |
| Employees | 322 | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 2017 |
| Metric | BLX | ANAB |
|---|---|---|
| Price | $43.11 | $43.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $59.90 |
| AVG Volume (30 Days) | 139.8K | ★ 407.6K |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | ★ 5.67% | N/A |
| EPS Growth | ★ 9.67 | N/A |
| EPS | ★ 6.00 | N/A |
| Revenue | ★ $308,426,000.00 | $169,467,000.00 |
| Revenue This Year | $18.35 | $135.45 |
| Revenue Next Year | $6.56 | N/A |
| P/E Ratio | $7.34 | ★ N/A |
| Revenue Growth | 10.24 | ★ 196.42 |
| 52 Week Low | $31.14 | $12.21 |
| 52 Week High | $48.38 | $52.47 |
| Indicator | BLX | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 36.68 | 45.58 |
| Support Level | $43.60 | $46.89 |
| Resistance Level | $44.73 | $52.47 |
| Average True Range (ATR) | 0.78 | 2.25 |
| MACD | -0.09 | -0.96 |
| Stochastic Oscillator | 2.56 | 16.95 |
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).